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Abstract
Background: Multiple prevention interventions, including early antiretroviral therapy initiation, may reduce HIV
incidence in hyperendemic settings. Our aim was to predict the short-term impact of various single and combined
interventions on HIV spreading in the adult population of Ndhiwa subcounty (Nyanza Province, Kenya).
Methods: A mathematical model was used with data on adults (15–59 years) from the Ndhiwa HIV Impact in
Population Survey to compare the impacts on HIV prevalence, HIV incidence rate, and population viral load
suppression of various interventions. These interventions included: improving the cascade of care (use of
three guidelines), increasing voluntary medical male circumcision (VMMC), and implementing pre-exposure
prophylaxis (PrEP) use among HIV-uninfected women.
Results: After four years, improving separately the cascade of care under the WHO 2013 guidelines and under the
treat-all strategy would reduce the overall HIV incidence rate by 46 and 58 %, respectively, vs. the baseline rate, and by
35 and 49 %, respectively, vs. the implementation of the current Kenyan guidelines. With conservative and optimistic
scenarios, VMMC and PrEP would reduce the HIV incidence rate by 15–25 % and 22–28 % vs. the baseline, respectively.
Combining the WHO 2013 guidelines with VMMC would reduce the HIV incidence rate by 35–56 % and combining
the treat-all strategy with VMMC would reduce it by 49–65 %. Combining the WHO 2013 guidelines, VMMC, and PrEP
would reduce the HIV incidence rate by 46–67 %.
Conclusions: The impacts of the WHO 2013 guidelines and the treat-all strategy were relatively close; their
implementation is desirable to reduce HIV spread. Combining several strategies is promising in adult populations of
hyperendemic areas but requires regular, reliable, and costly monitoring.
Keywords: HIV, Hyperendemic settings, Mathematical models, Antiretroviral therapy, Male circumcision, Pre-exposure
prophylaxis
Background
Globally, nearly 33 million people are infected with
HIV [1]. Although the incidence rate of HIV seems to
decrease, the epidemic continues to spread and the
situation remains extremely concerning in Sub-Saharan
Africa (70 % of the global burden) [1].
Antiretroviral therapy (ART) has greatly reduced HIV-
AIDS-related mortality and morbidity in resource-limited
countries [2–4] but inequalities in access to therapy still
exist [1]. ART is effective in preventing mother-to-child
transmission (PMTCT) [5, 6] and sexual transmission of
HIV within serodiscordant couples [7–9]. This suggests
that increasing ART coverage, thus the number of sero-
positive patients with undetectable viral loads (VL), should
reduce HIV incidence.
Between 2005 and 2007, three clinical trials in South
Africa, Kenya, and Uganda have shown that male cir-
cumcision may reduce the risk of acquiring HIV by 60 %
[10–12]. More recently, community cross-sectional surveys
have shown that increasing the prevalence of circumcision
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among 15–49 years old men was associated with a
reduction of HIV incidence as estimated by BED-assays
[13]. Besides, since the 2000s, another prevention strat-
egy, pre-exposure prophylaxis (PrEP), is being devel-
oped. PrEP is the use of antiretroviral drugs (oral or
topical) to prevent HIV acquisition by vulnerable indi-
viduals. However, to date, PrEP trials in Sub-Saharan
Africa have shown discordant results that depended on
the adherence to the treatment [14–19].
Currently, in collaboration with “Médecins Sans Fron-
tières” (Doctors Without Borders), Epicentre is planning
a strategy to reduce HIV incidence in Ndhiwa. Ndhiwa
is a subcounty of Homa-Bay County in Nyanza region,
the Kenyan area the most affected by HIV [20]. In 2012,
Epicentre conducted a subcounty-representative cross-
sectional population survey, the Ndhiwa HIV Impact in
Population Survey (NHIPS), to collect information on
the HIV burden in this subcounty; the adult (15–59
years) HIV prevalence was estimated to be 24.1 % [21].
A deterministic compartment-based model calibrated to
the NHIPS detailed local data was then built to support
operational decisions [22].
In the present study, the model is extended to account
for population VL (PVL; i.e., the VL in diagnosed and
undiagnosed individuals on ART or not). The aim was
to predict the short-term impacts of several (single and
combined) interventions on HIV prevalence, HIV inci-
dence, and PVL suppression (i.e., the proportion of
HIV-positive individuals with undetectable VL within
the whole HIV-positive population) in the adult popula-
tion (15–59 years old).
Methods
Study setting and NHIPS design
Ndhiwa has a population of 172,000 inhabitants of whom
nearly 76,880 are aged 15 to 59 years: 42,250 women and
34,630 men. Ndhiwa belongs to Nyanza region which has
the highest HIV prevalence rate in Kenya.
The NHIPS is a subcounty-representative cross-sectional
population survey conducted from September to November
2012. It used the Demographic and Health Surveys (DHS)
[23] methodology to collect information regarding the
HIV epidemic in Ndhiwa [21]. The NHIPS consisted of
a household questionnaire, an individual questionnaire,
and laboratory tests (HIV test, CD4 cell count, assays
for recent infection, and VL). Overall, 165 clusters of
20 households were randomly selected. The 3300 suc-
cessfully interviewed households in the survey included
16,198 persons (8493 women and 7705 men), of whom
6833 were eligible and 6076 agreed to participate. The
primary objective of the NHIPS was to estimate HIV
incidence using assays for recent infection. The second-
ary objectives included determining HIV prevalence,
the proportion of HIV-positive respondents in need of
ART, ART coverage, the proportion of HIV-positive
respondents with undetectable VL, HIV testing cover-
age, the proportion of medically circumcised men, and
the access to PMTCT services.
The key HIV indicators (prevalence, incidence, steps
of the cascade of care) estimated from the NHIPS have
been given elsewhere [21]. Briefly, the overall HIV preva-
lence was 24.1 % (95 % confidence interval [CI]: 23.0–
25.2). This prevalence was higher in women (26.7 %, 95 %
CI: 25.3–28.3) than in men (19.8 %, 95 % CI: 18.2–21.6)
and was more than two-fold higher in people aged 30–44
years than in those aged 15–29 years (34.7 %, 95 % CI:
32.4–30.8, vs. 16.8 %, 15.4–18.1).
Model and assumptions
To reach the objectives, we used a modified compartmen-
tal model designed to describe HIV transmission, the
untreated disease progression, and ART use in the general
population [22]. The model split the population into com-
partments according to sex, age (45 one-year strata from
15 to 59 years), and HIV status: HIV-negative (or suscep-
tible) individuals, untreated HIV-positive individuals with
CD4 cell count >350 cells/mm3 (compartment I1), un-
treated HIV-positive individuals with CD4 cell count ≤350
cells/mm3 (compartment I2), and HIV-positive individuals
on ART (compartment T). The estimates of the model
parameters by sex and age group (15–24, 25–34, 35–59
years) and the estimates of the distributions of the
subcounty population among the compartments by sex,
age, and HIV status were based on the NHIPS data as de-
scribed elsewhere [22] (see Additional file 1).
Here, we add information on the PVL to the force of
infection: the number of individuals in each compart-
ment was weighted by the proportion of individuals with
VL <1000 copies/mL (see Additional file 1). This propor-
tion was considered constant over time: 10 and 8 % in
compartment I1, 8 and 5 % in compartment I2, and 82
and 84 % in compartment T, for women and men,
respectively (proportions stemming from the NHIPS).
The infectiousness of individuals with VL below this
threshold was assumed to be reduced by 96 % [24].
Interventions modelled
The interventions modelled here are:
No change in the current interventions
Here, all the model parameters as estimated by the
NHIPS (particularly, treatment and circumcision rates)
were considered stable over the four-year simulation
time.
Improving the cascade of care
This intervention explored the impact of improving the
cascade of care with a focus on increasing ART coverage
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(through expanding the screening and enhancing the
linkage to care) and increasing PVL suppression. For
this intervention, three ART initiation recommenda-
tions were compared: a) the current Kenyan guidelines:
CD4 ≤ 350 cells/mm3 (PMTCT option A); b) the WHO
2013 guidelines: CD4 ≤ 500 cells/mm3 plus PMTCT op-
tion B+ (i.e., lifelong ART for all HIV-positive pregnant
and breastfeeding women whatever their CD4 cell
count) [25]; and, c) treat all HIV-positive subjects what-
ever the CD4 cell count. In these three recommenda-
tions, it is assumed that the overall ART coverage
among eligible individuals at the end of the four-year
simulation time would reach 80 % (conservative simula-
tion protocol) or 90 % (optimistic simulation protocol;
Table 1). To do this in the three recommendations, the
transition rate (or flow) between compartments I2 and
T was changed. Moreover, in settings b and c, a transi-
tion rate was added between compartments I1 and T
and its value was assumed to increase linearly over the
first year and finally equal the transition rate between
compartments I2 and T; in setting b, this transition rate
was multiplied by the proportion of individuals with
CD4 cell counts ≤500 cells/mm3 or pregnant or breast-
feeding HIV-positive women (proportions stemming
from the NHIPS).
Voluntary medical male circumcision (VMMC)
This intervention assumed that, overall, 50 % or 80 %
(conservative or optimistic simulation protocol, respect-
ively) of HIV-negative men would be circumcised at the
end of the four-year simulation time with a linear in-
crease over time; however, these proportions were given
various values depending on the age group (Table 1).
The protective effect of circumcision was assumed to
reduce female–male transmission by 60 % [10–12].
Pre-exposure prophylaxis (PrEP) in women
This intervention assumed that, overall, 34 % or 51 %
(conservative or optimistic simulation protocol, respect-
ively) of HIV-negative women would use PrEP at the end
of the four-year simulation time with a linear increase
over time; however, these proportions were given various
values depending on the age group (Table 1). The protect-
ive effect of PrEP was assumed to reduce male–female
transmission by 50 %.
Combined interventions
In the first combined intervention, the WHO 2013 guide-
lines were combined with VMMC (“ART & VMMC”). In
the second, the WHO 2013 guidelines were combined
with both VMMC and PrEP (“ART, VMMC, & PrEP”). In
these combinations, the conservative (or optimistic)
simulation protocol kept the conservative (or optimis-
tic) simulation protocol of each single intervention. For
comparison purposes, we combined also the current
Kenyan guidelines with VMMC as well as the treat-all
strategy with VMMC.
These interventions were compared with respect to
different predicted outcomes: the prevalence, the inci-
dence rate, the incidence rate ratio (i.e., the incidence
rate at end of the four-year simulation time divided by
the incidence rate at baseline), and the PVL suppression
reached after four years. PVL suppression was defined as
the proportion of HIV-positive subjects with a VL <1000
copies/mL (with the use of the compartment-specific
proportions given in “Model and assumptions”).
Results
Single interventions
In the short term, under scenario “No change in the
current interventions”, the HIV incidence rate would be
reduced by 7 % (1 % in men and 8 % in women) whereas
the prevalence would reach 25.3 % (19.1 % in men and
30.6 % in women). In the short term, with both conser-
vative and optimistic simulation protocols, the treat-all
strategy would have the greatest impact on reducing
HIV incidence rate in men (by 41 and 54 %, respectively)
and women (by 45 and 59 %, respectively; Figs. 1 and 2)
followed by the WHO 2013 guidelines in men (by 31
and 47 %) and women (by 27 and 44 %). VMMC would
Table 1 Baseline coverage of the interventions stemming from
the NHIPS (2012) and simulation protocols of the interventions
modelled
Interventions modelled Baseline Simulation protocol
Conservative Optimistic
Antiretroviral therapy coverage
among eligible subjects (%)
CD4≤ 350 cells/mm3 69 % 80 % 90 %
CD4≤ 500 cells/mm3 or PMTCT
option B+
51 % 80 % 90 %
All-CD4 40 % 80 % 90 %
Voluntary medical male circumcision
among uninfected men
15–24 years 42 % 75 % 90 %
25–34 years 17 % 30 % 70 %
35–59 years 5 % 10 % 60 %
All 25 % 50 % 80 %
Pre-exposure prophylaxis among
uninfected women
15–24 years - 60 % 80 %
25–34 years - 10 % 30 %
35–59 years - 10 % 20 %
All - 34 % 51 %
PMTCT B+ Prevention of mother-to-child transmission of HIV with lifelong ART
for all-HIV-positive pregnant and breastfeeding women whatever their CD4
cell count
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also have a great impact on reducing the incidence rate
(by 15 and 25 %) but a higher impact among men (the
direct target) than among women (18 and 38 % vs. 11
and 16 % reduction, respectively). PrEP would also have
a great impact on the overall HIV incidence (by 22 and
28 %); however, it would have a higher impact among
women (the direct target) than among men (29 and
37 % vs. 6 and 8 % reduction). All interventions would
slightly increase HIV prevalence over the four years
(1.0–1.2x the baseline) but this increase would be the
lowest with the treat-all strategy.
Considering a 90 % ART coverage, the treat-all strategy
would have a higher impact on the HIV incidence rate
than the WHO 2013 guidelines or the current Kenyan
guidelines, the reduction being respectively 58, 46,
and 17 % vs. the baseline rate (see Additional file 1:
Figure A2).
In the NHIPS, the baseline PVL suppression was about
37 %. The treat-all strategy over four years would cause
the greatest PVL suppression: 68 and 75 % respectively
with the conservative and optimistic simulation proto-
cols vs. 47 % with no change in the current interventions
(see Additional file 1: Figure A3). The WHO 2013 guide-
lines would lead to 60 and 70 % PVL suppression,
respectively.
Depending on the sex and the age group, the treat-all
strategy would cause the greatest reduction in the HIV
incidence rate (39 to 46 % with the conservative simula-
tion protocol and 52 to 59 % with the optimistic simula-
tion protocol), followed by the WHO 2013 guidelines
(28 to 34 % with the conservative simulation protocol
and 45 to 50 % with the optimistic simulation protocol,
Fig. 3). VMMC would reduce the HIV incidence rate in
men: 4 to 24 % in the conservative simulation protocol
Fig. 1 Short-term changes in HIV prevalence and incidence rates of single interventions with conservative simulation protocols
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and 35 to 41 % in the optimistic simulation protocol.
PrEP would reduce HIV incidence rate in women: 14 to
37 % with the conservative simulation protocol and 20
to 46 % with the optimistic simulation protocol, mostly
in the targeted 15–24 age group. The current Kenyan
guidelines would have a modest short-term impact on
the HIV incidence rate (a 6 to 20 % reduction vs. the
baseline) because the baseline ART coverage is already
close to 70 %.
Combined interventions
Combined interventions would have greater impacts on
HIV prevalence and incidence rate than single interven-
tions. Precisely, “ART, VMMC, & PrEP” would have the
greatest impact on the overall incidence rate (46 and
67 % reduction in the conservative and optimistic simu-
lation protocol, respectively, vs. the baseline rate; see
Additional file 1: Figure A4). “ART & VMMC” would
have a great impact on the incidence rate (35 and 56 %
reduction in the conservative and optimistic simulation
protocol, respectively, vs. the baseline rate).
Depending on the sex and the age group, “ART,
VMMC, & PrEP” would have the greatest impact on the
HIV incidence rate; it would reduce it by 34 to 52 %
with the conservative simulation protocol and by 55 to
71 % with the optimistic simulation protocol vs. the
baseline rate (Fig. 4). “ART & VMMC” would reduce the
incidence rate by 30 to 47 % with the conservative simu-
lation protocol and by 49 to 69 % with the optimistic
simulation protocol vs. the baseline rate.
Over four years, the incidence rate would be reduced
by 24 and 33 % with the combination of the current
Kenyan guidelines plus VMMC and by 49 and 65 % with
the combination of a treat-all strategy plus VMMC.
Discussion
A deterministic compartmental model was used to in-
vestigate the short-term impacts of various single and
Fig. 2 Short-term changes in HIV prevalence and incidence rates of single interventions with optimistic simulation protocols
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Fig. 3 Predicted incidence rate ratios after four years of single interventions by sex and age group
Fig. 4 Predicted incidence rate ratios after four years of combined interventions by sex and age group. “ART & VMMC” included “cascade of care”
intervention under the WHO 2013 guidelines combined with voluntary medical male circumcision (VMMC). “ART, VMMC & PrEP” included “cascade of
care” intervention under the WHO 2013 guidelines with VMMC and female pre-exposure prophylaxis
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combined interventions on HIV incidence in the adult
population (15–59 years old) of Ndhiwa subcounty,
Kenya.
Our results showed that an improvement of the
“cascade of care” according to the WHO 2013 guide-
lines or a treat-all strategy would have a high impact
on the HIV incidence rate (46 and 58 % reduction
vs. the baseline rate). The treat-all strategy would have a
greater impact among women than among men whereas
the WHO 2013 guidelines would have a greater impact
among men than among women; this is due to the fact
that, in the latter case, a higher proportion of women are
eligible for ART, which results in a lower weighted preva-
lence of HIV in women than in men. In comparison with
the current Kenyan guidelines, the optimistic simulation
protocol with the WHO 2013 guidelines and the treat-all
strategy would result in a 35 % and 49 % incidence reduc-
tion, respectively, after four years. Previous mathematical
models applied to Sub-Saharan populations have shown
that long-term ART interventions (especially ‘test and
treat’ strategy) would substantially reduce the HIV inci-
dence rate [26–33].
Here, the impacts of improving the “cascade of care”
under the WHO 2013 guidelines and those of the treat-
all strategy were relatively close. This may be explained
by the high proportion of eligible individuals under the
WHO 2013 guidelines in NHIPS (81 % of all HIV-
positive individuals) [21]. Moreover, the time from infec-
tion to reaching a CD4 cell count <500 cells/mm3 has
been estimated to be relatively short [34]. This would
result in quick eligibility of individuals for ART. In
addition, another modelling study showed close impacts
of the treat-all strategy and an extension of the eligibility
for ART (from <350 to <500 CD4 cells/mm3): using
several mathematical models, it has been shown that, in
South Africa, this extension would prevent 5 to 12 %
new infections whereas an extension to all HIV-positive
individuals would prevent 9 to 32 % new infections over
20 years depending on the mathematical model and
assuming no additional testing and linkage to care [35].
These results suggest that whatever the strategy (treat-
all or treat subjects with <500 CD4 cells/mm3), the main
effort would still be to test and offer treatment.
Our results showed that, in the short term, the PVL
suppression would reach 60 to 70 % under the WHO
2013 guidelines or 68 to 75 % under the treat-all strat-
egy, depending on the simulation protocol, whereas it
would be 47 % with no change in the current interven-
tions. To our knowledge, no previous modelling study
has calculated this metric yet. Actually, this metric is
interesting because it has been shown to be negatively
associated with incidence [36–38] and can be more eas-
ily estimated than incidence. Moreover, this metric will
be increasingly used with the potential future availability
of point-of-care viral load tests in resource-limited
settings.
The treat-all strategy could simplify the strategies aim-
ing at increasing ART coverage but would raise ethical
questions (ART for “healthy” people), long-term toxicity,
viral resistance issues, and cost issues. However, initiat-
ing ART at <500 CD4 cells or even earlier has shown
individual clinical benefits [39–41] and recent models
have shown that extending ART eligibility to <500 CD4
cells/mm3 or to all HIV-positive individuals would be
cost-effective [35]. In fact, randomized controlled trials
are currently addressing the issues of acceptability and
feasibility of offering early ART and the impact of early
treatment on HIV incidence [42].
Our results suggest that VMMC alone would reduce
the overall incidence rate by 15 to 25 %, depending on
the simulation protocol. Its impact is expected to be
higher in men than in women because the former are
directly protected by circumcision. Previous mathemat-
ical models applied to Sub-Saharan populations showed
that, in the long-term, circumcision would also benefit
indirectly to women and uncircumcised men [43–47].
The present results suggest that female PrEP, as a
single intervention, would reduce the overall HIV inci-
dence rate by 22 to 28 % according to the simulation
protocol. This intervention was included here despite its
costs and previous mixed results in Sub-Saharan Africa
(discrepancies explained by differences in adherence levels
[19]). Previous models of PrEP applied to Sub-Saharan
African countries have shown short-, middle-, and long-
term protection against new HIV infections in the general
population [48–50] and in high-risk populations (female
sex workers and clients [51], people with high sexual
activity [48], young people [48], young women [49] or
serodiscordant couples [52]). Some models have also
shown that PrEP may be cost-effective in hyperendemic
settings [49, 50, 52].
The present results show that combining the WHO
2013 guidelines with VMMC would reduce the HIV inci-
dence rate by 35 to 56 % according to the simulation
protocol and that combining treat-all with VMMC would
reduce HIV incidence by 49 to 65 %. These results are
consistent with those of a recent modelling of data from
KwaZulu-Natal (South Africa); i.e., a 63 % reduction in
the HIV incidence rate within four years with a combin-
ation of four interventions: increasing the coverage of test-
ing and counselling, reducing risky behaviour, increasing
the coverage of VMMC, and increasing ART coverage
(with a ‘test and treat’ strategy) [53]. Recently, Cori et al.
estimated that a combination of increasing home-based
voluntary testing and counselling, increasing VMMC
coverage, and increasing ART coverage with a treat-all
strategy over three years would lead to a 60 % reduction
vs. no change in the current interventions [54]. Here,
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making the same calculation, the WHO 2013 guidelines
with VMMC would lead to a 37 to 53 % reduction. Com-
bining the WHO 2013 guidelines with VMMC and PrEP
would reduce the HIV incidence rate by 46 to 67 %. Previ-
ous models have shown that combining ART and PrEP
would have a higher impact on HIV incidence than ART
alone [52, 55].
The strengths of our study are: i) the calibration of
a model on the basis of detailed local and recent
population-based data (including individual CD4 mea-
surements); ii) the availability of viral load measurements
at the population level (i.e., in both diagnosed and undiag-
nosed individuals, under treatment or not), making it
possible to estimate the PVL suppression in the short
term after various interventions; and, iii) the intervention
scenarios were based on the current levels of coverage of
these interventions by sex and by age classes.
Our analysis had some limitations. First, the various
steps in the cascade of care were implicitly modelled;
however, the success of an ART intervention depends on
each step of the cascade of care and, at each step, cohort
attrition may occur because of insufficient screening
policy, fear of diagnosis or treatment, lack of access to
ART, etc. [56]. Second, in our optimistic simulation proto-
col, the proportion of HIV-negative men to circumcise in
age group 35–59 years is relatively high; however, not all
men would accept circumcision. Actually, in the ANRS-
12126 Male Circumcision Project, the proportion of
circumcised men raised over three years from 6 % in age
group 35–39 years and 17 % in age group 40–49 years to
37 and 34 %, respectively [13]; this suggests that men in
age group 35–49 years are likely to accept circumcision.
Third, risk compensation was not modelled. Risk compen-
sation could reduce the benefit of the interventions at the
population level. Some models relative to circumcision, as
a single intervention, have shown that a high increase in
risky behaviour may reduce the benefits from VMMC
regarding HIV prevalence or incidence [44–46, 57, 58].
Fourth, we did not consider drug resistance in HIV-
positive individuals on ART or in individuals using PrEP;
indeed, drug resistance can also reduce the benefit of ART
and PrEP at the population level. Mathematical models
have shown that an increase in ART coverage would in-
crease the prevalence of drug resistance in resource-
limited settings [27, 28, 59]. Recent models including ART
and PrEP suggest that the majority of resistance cases
were rather due to ART than to PrEP, ART coverage being
higher than PrEP coverage [55, 60].
The likelihood of success of a HIV prevention or treat-
ment intervention may be increased by door-to-door
home-based interventions with voluntary HIV testing
and counselling and with the support of the community.
Depending on the HIV status, counselling may target
VMMC or/and focus on HIV care and referral to care
clinics. This type of campaign has been associated with
high ART coverage and high VMMC prevalence in a
rural/semi-urban area in Uganda [61] and with high
ART coverage and high level of PVL suppression in rural
KwaZulu-Natal [62]. Such a campaign may be success-
fully implemented in Ndhiwa given the high level of
participation in the NHIPS survey (response rate close
to 90 %) [21].
Conclusions
The implementation of the WHO 2013 guidelines is
expected to be efficient in reducing the spread of HIV.
Combining strategies is promising in reducing HIV inci-
dence in adult populations of hyperendemic areas, but
requires careful monitoring over time.
Ethics approval and consent to participate
Ethical approval was obtained in Kenya from the Kenya
Medical Research Institute Ethical Review Committee
(KEMRI, ref 347) and in France from the “Comité de Pro-
tection des Personnes d’Ile de France” (CPP, ref 12056).
Written consent for participating in the study and under-
going HIV testing was obtained from each participant
prior to the survey interview.
Availability of data and materials
The readers interested in using the NHIPS data may
contact D. Maman at Epicentre, 8 rue Saint Sabin, F-75010
Paris, France.
Additional file
Additional file 1: Appendix. Technical appendix and supplementary
figures. (PDF 685 kb)
Abbreviations
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy;
DHS: Demographic and Health Surveys; HIV: human immunodeficiency virus;
NHIPS: the Ndhiwa HIV Impact in Population Survey; PMTCT: prevention of
mother-to-child transmission; PrEP: pre-exposure prophylaxis; PVL: population
viral load; VL: viral load; VMMC: voluntary medical male circumcision;
WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SB, DM, BR, IM, BK, RE, and JFE conceived and designed the experiments.
SB, BR, and RE performed the experiments. SB, DM, BR, IM, BK, RE, and JFE
analysed the results. SB, BR, and RE wrote the first draft of the manuscript.
SB, DM, BR, IM, BK, RE, and JFE contributed to the writing of the manuscript.
All authors read and approved final manuscript.
Acknowledgements
The authors are grateful to the Ndhiwa Community, the NHIPS field
study team, and the study participants. They are also grateful to S. Masson,
I. Nabaasa, S. Crisan, J. Ben Ferhat, and S. Balandine from Epicentre; to
A. Heinzelmann, W. Hennequin, J. Coyne, and A. Munger from Médecins
Sans Frontières; to J.O. Lusi, I. Masoni, J. Ocholla, and A. Nyibaye from the
Kenyan Ministry of Health; to C. Zeh and A. Kim from the US Centers for
Blaizot et al. BMC Infectious Diseases  (2016) 16:189 Page 8 of 10
Disease Control and Prevention-Kenya; and to V. Opollo and S. Omondi from
the Kenyan Medical Research Institute.
They also thank Jean Iwaz (Hospices Civils de Lyon, France) for many helpful
comments, suggestions, and revisions of various versions of the manuscript.
Funding
The NHIPS study was funded and sponsored by Médecins Sans Frontières
(France) and conducted by Epicentre (France) in collaboration with the
Kenyan Ministry of Medical Services, the Kenyan Ministry of Public Health
and Sanitation, the National AIDS and STDs Control Programme (NASCOP,
Nairobi, Kenya), the Kenyan Medical Research Institute (KEMRI, Nairobi,
Kenya), the KEMRI/CDC (Kisumu, Kenya) and Hospices Civils de Lyon (France).
Author SB was financially supported by Agence Nationale de Recherche sur
le SIDA et les hépatites virales, ANRS (France REcherche Nord & sud SIDA-HIV
Hépatites: FRENSH), France.
Author details
1Service de Biostatistique, Hospices Civils de Lyon, F-69003 Lyon, France.
2Université de Lyon, F-69000 Lyon, France. 3Université Lyon 1, F-69100
Villeurbanne, France. 4CNRS UMR 5558, Equipe Biostatistique-Santé,
Laboratoire de Biométrie et Biologie Evolutive, F-69100 Villeurbanne, France.
5Epicentre, F-75011 Paris, France. 6National AIDS and STDs Control Program,
Nairobi, Kenya. 7Médecins Sans Frontières, Nairobi, Kenya. 8UMI 233
TransVIHMI, Institut de Recherche pour le Développement, Université
Montpellier 1, F-34000 Montpellier, France.
Received: 22 May 2015 Accepted: 18 April 2016
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report:
UNAIDS report on the global AIDS epidemic. Geneva: Joint United Nations
Programme on HIV/AIDS (UNAIDS); 2013.
2. Gargano JW, Laserson K, Muttai H, Odhiambo F, Orimba V, Adamu-Zeh M,
et al. The adult population impact of HIV care and antiretroviral therapy in a
resource poor setting, 2003–2008. AIDS. 2012;26(12):1545–54.
3. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life
expectancy in rural South Africa: valuing the scale-up of HIV treatment.
Science. 2013;339(6122):961–5.
4. Chihana M, Floyd S, Molesworth A, Crampin AC, Kayuni N, Price A, et al.
Adult mortality and probable cause of death in rural northern Malawi in the
era of HIV treatment. Trop Med Int Health. 2012;17(8):e74–83.
5. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al.
Reduction of maternal-infant transmission of human immunodeficiency
virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group
Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.
6. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal
levels of plasma human immunodeficiency virus type 1 RNA and the risk
of perinatal transmission. Women and Infants Transmission Study Group.
N Engl J Med. 1999;341(6):394–402.
7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F,
et al. Viral load and heterosexual transmission of human immunodeficiency
virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–9.
8. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C.
Effectiveness of highly active antiretroviral therapy in reducing heterosexual
transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96–101.
9. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV
according to viral load and antiretroviral therapy: systematic review and
meta-analysis. AIDS. 2009;23(11):1397–404.
10. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A.
Randomized, controlled intervention trial of male circumcision for reduction
of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.
11. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al.
Male circumcision for HIV prevention in young men in Kisumu, Kenya:
a randomised controlled trial. Lancet. 2007;369(9562):643–56.
12. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male
circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Lancet. 2007;369(9562):657–66.
13. Auvert B, Taljaard D, Rech D, Lissouba P, Singh B, Bouscaillou J, et al.
Association of the ANRS-12126 male circumcision project with HIV levels
among men in a South African township: evaluation of effectiveness using
cross-sectional surveys. PLoS Med. 2013;10(9):e1001509.
14. Microbicide Trials Network (MTN). http://www.mtnstopshiv.org/node/2003.
Accessed March 2014.
15. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C,
Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral
microbicide, for the prevention of HIV infection in women. Science.
2010;329(5996):1168–74.
16. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al.
Preexposure prophylaxis for HIV infection among African women. N Engl J
Med. 2012;367(5):411–22.
17. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al.
Antiretroviral prophylaxis for HIV prevention in heterosexual men and
women. N Engl J Med. 2012;367(5):399–410.
18. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM,
et al. Antiretroviral preexposure prophylaxis for heterosexual HIV
transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
19. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV
prevention: where have we been and where are we going? J Acquir
Immune Defic Syndr. 2013;63 Suppl 2:S122–9.
20. Kimanga DO, Ogola S, Umuro M, Ng’ang’a A, Kimondo L, Murithi P, et al.
Prevalence and incidence of HIV infection, trends, and risk factors among
persons aged 15–64 years in Kenya: results from a nationally representative
study. J Acquir Immune Defic Syndr. 2014;66 Suppl 1:S13–26.
21. Maman D, Zeh C, Mukui I, Kirubi B, Masson S, Opolo V, et al. Cascade of HIV
care and population viral suppression in a high-burden region of Kenya.
AIDS. 2015;29(12):1557–65.
22. Blaizot S, Riche B, Maman D, Mukui I, Kirubi B, Etard JF, et al. Estimation and
short-term prediction of the course of the HIV epidemic using demographic
and health survey methodology-like data. PLoS One. 2015;10(6):e0130387.
23. Measure DHS, ICF International. Available at URL: http://dhsprogram.com.
Accessed August 2014.
24. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC,
Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral
therapy. N Engl J Med. 2011;365(6):493–505.
25. World Health Organization. Consolidated guidelines on general HIV care
and the use of antiretroviral drugs for treating and preventing HIV infection:
recommendations for a public health approach. Geneva: World Health
Organization; 2013.
26. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals
in resource-poor settings: preventing HIV infections whilst controlling drug
resistance. Curr Drug Targets Infect Disord. 2003;3(4):345–53.
27. Nagelkerke NJ, Jha P, de Vlas SJ, Korenromp EL, Moses S, Blanchard JF, et al.
Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions
to prevent transmission. Bull World Health Organ. 2002;80(2):89–96.
28. Garnett GP, Bartley L, Grassly NC, Anderson RM. Antiretroviral therapy
to treat and prevent HIV/AIDS in resource-poor settings. Nat Med.
2002;8(7):651–4.
29. Johnson LF, Dorrington RE. Modelling the demographic impact of
HIV/AIDS in South Africa and the likely impact of interventions. Demogr
Res. 2006;14:22.
30. Wilson DP, Kahn J, Blower SM. Predicting the epidemiological impact of
antiretroviral allocation strategies in KwaZulu-Natal: the effect of the
urban–rural divide. Proc Natl Acad Sci U S A. 2006;103(38):14228–33.
31. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM,
Santas CC. Cost-effectiveness of alternative strategies for initiating and
monitoring highly active antiretroviral therapy in the developing world.
J Acquir Immune Defic Syndr. 2007;46(1):91–100.
32. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal
voluntary HIV testing with immediate antiretroviral therapy as a
strategy for elimination of HIV transmission: a mathematical model.
Lancet. 2009;373(9657):48–57.
33. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination
by ‘test and treat’ in hyperendemic settings. AIDS. 2010;24(5):729–35.
34. Fast PE, Price MA, Rida WN, Kamali A, Karita E. WHO’s new guidelines for
antiretroviral treatment. Lancet. 2013;382(9907):1778–9.
35. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A,
et al. Health benefits, costs, and cost-eff ectiveness of earlier eligibility
for adult antiretroviral therapy and expanded treatment coverage: a
combined analysis of 12 mathematical models. Lancet Glob Health.
2014;2:e23–34.
Blaizot et al. BMC Infectious Diseases  (2016) 16:189 Page 9 of 10
36. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal
community plasma HIV-1 RNA concentrations and incidence of HIV-1
among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
37. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al.
Decreases in community viral load are accompanied by reductions in new
HIV infections in San Francisco. PLoS One. 2010;5(6):e11068.
38. Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, et al. Use of the
community viral load as a population-based biomarker of HIV burden. AIDS.
2012;26(3):345–53.
39. Lockman S, Sax P. Treatment-for-prevention: clinical considerations. Curr
Opin HIV AIDS. 2012;7(2):131–9.
40. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A,
Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive
therapy in Africa. N Engl J Med. 2015;373(9):808–22.
41. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S,
Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV
Infection. N Engl J Med. 2015;373(9):795–807.
42. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al.
Evaluation of the impact of immediate versus WHO recommendations-
guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249
TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal,
South Africa: study protocol for a cluster randomised controlled trial. Trials.
2013;14:230.
43. Boily MC, Desai K, Masse B, Gumel A. Incremental role of male circumcision
on a generalised HIV epidemic through its protective effect against other
sexually transmitted infections: from efficacy to effectiveness to population-
level impact. Sex Transm Infect. 2008;84 Suppl 2:ii28–34.
44. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP.
Understanding the impact of male circumcision interventions on the spread
of HIV in southern Africa. PLoS One. 2008;3(5):e2212.
45. Londish GJ, Murray JM. Significant reduction in HIV prevalence according
to male circumcision intervention in sub-Saharan Africa. Int J Epidemiol.
2008;37(6):1246–53.
46. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, et al. Male
circumcision for HIV prevention in sub-Saharan Africa: who, what and
when? AIDS. 2008;22(14):1841–50.
47. Hallett TB, Alsallaq RA, Baeten JM, Weiss H, Celum C, Gray R, et al. Will
circumcision provide even more protection from HIV to women and men?
New estimates of the population impact of circumcision interventions.
Sex Transm Infect. 2011;87(2):88–93.
48. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral
chemoprophylaxis on HIV-1 transmission in resource-limited settings.
PLoS One. 2007;2(9):e875.
49. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the
cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on
HIV-1 transmission in South Africa. PLoS One. 2010;5(11):e13646.
50. Verguet S, Stalcup M, Walsh JA. Where to deploy pre-exposure prophylaxis
(PrEP) in sub-Saharan Africa? Sex Transm Infect. 2013;89(8):628–34.
51. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact
of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India:
a simulation study. PLoS One. 2008;3(5):e2077.
52. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al.
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant
heterosexual couples in South Africa: a modelling study. PLoS Med.
2011;8(11):e1001123.
53. Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV,
et al. Understanding the potential impact of a combination HIV prevention
intervention in a hyper-endemic community. PLoS One. 2013;8(1):e54575.
54. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071
(PopART): a cluster-randomized trial of the population impact of an HIV
combination prevention intervention including universal testing and
treatment: mathematical model. PLoS One. 2014;9(1):e84511.
55. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy
and pre-exposure prophylaxis: combined impact on HIV transmission and
drug resistance in South Africa. J Infect Dis. 2013;208(2):224–34.
56. Kilmarx PH, Mutasa-Apollo T. Patching a leaky pipe: the cascade of HIV care.
Curr Opin HIV AIDS. 2013;8(1):59–64.
57. Alsallaq RA, Cash B, Weiss HA, Longini Jr IM, Omer SB, Wawer MJ, et al.
Quantitative assessment of the role of male circumcision in HIV
epidemiology at the population level. Epidemics. 2009;1(3):139–52.
58. Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, et al. The impact
of male circumcision on HIV incidence and cost per infection prevented:
a stochastic simulation model from Rakai, Uganda. AIDS. 2007;21(7):845–50.
59. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and
drug-resistant HIV in Africa: insights from empirical data and theoretical
models. AIDS. 2005;19(1):1–14.
60. van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW,
et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug
resistance in sub-Saharan Africa: a comparison of mathematical models.
AIDS. 2013;27(18):2943–51.
61. Tumwebaze H, Tumwesigye E, Baeten JM, Kurth AE, Revall J, Murnane PM,
et al. Household-based HIV counseling and testing as a platform for referral
to HIV care and medical male circumcision in Uganda: a pilot evaluation.
PLoS One. 2012;7(12):e51620.
62. van Rooyen H, Barnabas RV, Baeten JM, Phakathi Z, Joseph P, Krows M, et al.
High HIV testing uptake and linkage to care in a novel program of home-
based HIV counseling and testing with facilitated referral in KwaZulu-Natal,
South Africa. J Acquir Immune Defic Syndr. 2013;64(1):e1–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Blaizot et al. BMC Infectious Diseases  (2016) 16:189 Page 10 of 10
